Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients

INTRODUCTION: The measurement of body composition such as the skeletal muscle index (SMI) has been reported to be useful for predicting prognosis in hepatocellular carcinoma (HCC). In this study, we analyzed skeletal muscle change during sorafenib and lenvatinib therapy and the association between S...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Liver Cancer
Autors principals: Uchikawa, Shinsuke, Kawaoka, Tomokazu, Namba, Maiko, Kodama, Kenichiro, Ohya, Kazuki, Morio, Kei, Nakahara, Takashi, Murakami, Eisuke, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Takahashi, Shoichi, Chayama, Kazuaki, Aikata, Hiroshi
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2020
Matèries:
Original Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7206610/
https://ncbi.nlm.nih.gov/pubmed/32399429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503829
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars